SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
SELLAS Life Sciences Group (NASDAQ: SLS), a late-stage clinical biopharmaceutical company, announced its participation in the 2024 Maxim Healthcare Virtual Summit. Dr. Angelos Stergiou, President and CEO of SELLAS, will engage in a fireside chat on Tuesday, October 15, 2024, at 9:00 am EDT.
The virtual summit will be hosted on the M-Vest platform, where investors can register to watch the fireside chat and schedule one-on-one meetings. SELLAS focuses on developing novel therapies for a broad range of cancer indications, positioning itself as a key player in the oncology therapeutics sector.
SELLAS Life Sciences Group (NASDAQ: SLS), un'azienda biopharmaceutica in fase avanzata di sviluppo clinico, ha annunciato la sua partecipazione al 2024 Maxim Healthcare Virtual Summit. Il Dr. Angelos Stergiou, Presidente e CEO di SELLAS, parteciperà a un fireside chat martedì 15 ottobre 2024, alle 9:00 EDT.
Il summit virtuale sarà ospitato sulla piattaforma M-Vest, dove gli investitori possono registrarsi per assistere al fireside chat e programmare incontri individuali. SELLAS si concentra sulla sviluppo di terapie innovative per una vasta gamma di indicazioni oncologiche, posizionandosi come un attore chiave nel settore della terapia oncologica.
SELLAS Life Sciences Group (NASDAQ: SLS), una empresa biofarmacéutica en etapa avanzada de desarrollo clínico, anunció su participación en el 2024 Maxim Healthcare Virtual Summit. El Dr. Angelos Stergiou, Presidente y CEO de SELLAS, participará en una charla informal el martes 15 de octubre de 2024, a las 9:00 a. m. EDT.
La cumbre virtual se llevará a cabo en la plataforma M-Vest, donde los inversores pueden registrarse para ver la charla y programar reuniones uno a uno. SELLAS se enfoca en desarrollar terapias novedosas para una amplia gama de indicaciones de cáncer, posicionándose como un actor clave en el sector de terapias oncológicas.
SELLAS Life Sciences Group (NASDAQ: SLS), 후기 단계 임상 바이오 제약 회사가 2024 Maxim Healthcare Virtual Summit에 참여한다고 발표했습니다. SELLAS의 회장 겸 CEO인 Dr. Angelos Stergiou는 2024년 10월 15일 화요일 오전 9:00 EDT에 파이어사이드 채팅을 진행할 예정입니다.
이번 가상 서밋은 M-Vest 플랫폼에서 진행되며 투자자들은 fireside chat을 시청하기 위해 등록하고, 일대일 미팅을 예약할 수 있습니다. SELLAS는 광범위한 암 적응증에 대한 새로운 치료법 개발에 중점을 두고 있으며, 종양학 치료제 분야의 주요 플레이어로 자리매김하고 있습니다.
SELLAS Life Sciences Group (NASDAQ: SLS), une entreprise biopharmaceutique en phase clinique avancée, a annoncé sa participation au 2024 Maxim Healthcare Virtual Summit. Le Dr. Angelos Stergiou, président et PDG de SELLAS, participera à une discussion informelle le mardi 15 octobre 2024, à 9h00 EDT.
Le sommet virtuel sera hébergé sur la plateforme M-Vest, où les investisseurs peuvent s'inscrire pour regarder la discussion et planifier des réunions en tête-à-tête. SELLAS se concentre sur le développement de nouvelles thérapies pour un large éventail d'indications cancéreuses, se positionnant comme un acteur clé dans le domaine des thérapeutiques en oncologie.
SELLAS Life Sciences Group (NASDAQ: SLS), ein biopharmazeutisches Unternehmen in der späten klinischen Entwicklungsphase, hat seine Teilnahme am 2024 Maxim Healthcare Virtual Summit bekannt gegeben. Dr. Angelos Stergiou, Präsident und CEO von SELLAS, wird am Dienstag, den 15. Oktober 2024, um 9:00 Uhr EDT an einem Fireside Chat teilnehmen.
Der virtuelle Gipfel wird auf der M-Vest-Plattform ausgerichtet, wo Investoren sich registrieren können, um den Fireside Chat zu verfolgen und Einzelgespräche zu planen. SELLAS konzentriert sich auf die Entwicklung neuartiger Therapien für ein breites Spektrum von Krebsindikationen und positioniert sich als bedeutender Akteur im Bereich der Onkologie-Therapeutika.
- None.
- None.
NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Dr. Angelos Stergiou, President and Chief Executive Officer of SELLAS, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024 at 9:00 am EDT.
Maxim Healthcare Virtual Summit Details:
Format: Fireside chat
Date: Tuesday, October 15, 2024
Time: 9:00 am EDT
The conference will be hosted on the M-Vest site and investors can register to watch the fireside chat and schedule 1x1 meetings here.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (formerly GFH009) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.
Investor Contact
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
SELLAS@lifesciadvisors.com
FAQ
When is SELLAS Life Sciences (SLS) participating in the Maxim Healthcare Virtual Summit?
Who will represent SELLAS Life Sciences (SLS) at the 2024 Maxim Healthcare Virtual Summit?
How can investors watch SELLAS Life Sciences' (SLS) fireside chat at the Maxim Healthcare Virtual Summit?
What is the focus of SELLAS Life Sciences (SLS) as a biopharmaceutical company?
